


Product Name : RP-3500
Cat. No. : PC-72315
CAS No. : 2417489-10-0
Molecular Formula : C₂₁H₂₆N₆O₃
Molecular Weight : 410.478
Target : ATM/ATR
Solubility : 10 mM in DMSO



Biological Activity

RP-3500 (RP3500, Camonsertib) is a novel potent, selective, orally bioavailable **ATR** inhibitor with IC₅₀ of 1.0 and 0.33 nM in biochemical and cell-based assays, respectively.

RP-3500 displays 30-fold selectivity over mTOR and >2,000-fold selectivity over ATM, DNA-PK, and PI3K α kinases.

RP-3500 inhibited phosphorylated checkpoint kinase 1 (pCHK1) (IC₈₀=18.6 nM) and induction of phosphorylated H2A.X variant histone (γ H2AX), phosphorylated DNA-PK catalytic subunit (pDNA-PKcs), and phosphorylated KRAB-associated protein 1 (pKAP1).

RP-3500 demonstrated potent single-agent efficacy and/or tumor regression in multiple xenograft models at minimum effective doses (MED) of 5 to 7 mg/kg once daily.

RP-3500 demonstrated superior efficacy when combined with PARP inhibitor olaparib or niraparib.

References

Anne Roulston, et al. *Mol Cancer Ther.* 2022 Feb;21(2):245-256.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com